Selected Publications (PubMed; GoogleScholar )
Implications of Mucin-Type O-Glycosylation in Alzheimer's Disease.
DOI: 10.3390/molecules30091895.
DOI: 10.1002/cbic.202400391
![]() |
![]() |
Targeting Siglec-Sialylated MUC1 Immune Axis in Cancer.
Preventative Cancer Vaccine-Elicited Human Anti-MUC1 Antibodies Have Multiple Effector Functions.
M.L. McKeague, J. Lohmueller, M.T. Dracz, N. Saadallah, E.D. Ricci, D.M. Beckwith, R. Ayyalasomayajula, M. Cudic, O.J. Finn Antibodies (Basel) 2024, 13(4):85.
DOI: 10.3390/antib13040085
Mucin-type O-Glycosylation Proximal to β-Secretase Cleavage Site Affects APP Processing and Aggregation Fate.
Y. Singh, D. Regmi, D. Ormaza, R. Ayyalasomayajula, N. Vela, G. Mundim, D. Du, D. Minond, M. Cudic Front. Chem. 2022, 10:859822.
DOI: 10.3389/fchem.2022.859822
Exploring Glycan Binding Specificity of Odorranalectin by Alanine Scanning Library.
Y. Singh, P. Cudic, M. Cudic Eur. J. of Org. Chem. 2022, 2022(28):e202200302.
DOI: 10.1002/ejoc.202200302
![]() |
![]() |
Calorimetric Analysis of the Interplay between Synthetic Tn Antigen-Presenting MUC1 Glycopeptides and Human Macrophage Galactose-Type Lectin.
D.M. Beckwith, F.G. FitzGerald, M.C. Rodriguez Benavente, E.R. Mercer, A.K. Ludwig, M. Michalak, H. Kaltner, J. Kopitz, H.-J. Gabius, M. Cudic Biochemistry 2021, 60:547–558.
DOI: 10.1021/acs.biochem.0c00942
Tyrosine O-GalNAc Alters the Conformation and Proteolytic Susceptibility of APP Model Glycopeptides.
Y. Singh, D. Ormaza, A. Massetti, D. Minond, M. Cudic
ACS Chem. Neurosci.
2021, 12:2974–2980.
DOI: 10.1021/acschemneuro.1c00387
TF-containing MUC1 glycopeptides fail to entice Galectin-1 recognition of tumor-associated Thomsen-Freidenreich (TF) antigen (CD176) in solution.
F.G. FitzGerald, M.C. Rodriguez Benavente, C. Garcia, Y. Rivero, Y. Singh, H. Wang, G.B. Fields, M. Cudic Glycoconj. J. 2020, 37(6):657–666.
DOI: 10.1007/s10719-020-09951-x
Tumor-associated O-glycans of MUC1: Carriers of the glyco-code and targets for cancer vaccine design.
D.M. Beckwith, M. Cudic Semin. Immunol. 2020, 47:101389.
DOI: 10.1016/j.smim.2020.101389
Positional Scanning MUC1 Glycopeptide Library Reveals the Importance of PDTR Epitope Glycosylation for Lectin Binding.Y. Singh, M.C. Rodriguez Benavente, M.H. Al-Huniti, D. Beckwith, R. Ayyalasomayajula, E. Patino, W.S. Miranda, A. Wade, M. Cudic J. Org. Chem. 2020, 85(3):1434–1445.
DOI: 10.1021/acs.joc.9b02396
Targeting cancer-specific glycans by cyclic peptide lectinomimics.
M.C. Rodriguez, A.B. Yongye, M. Cudic, K. Martinez Mayorga, E. Liu, B.M. Mueller, J. Ainsley, T. Karabencheva-Christova, C.Z. Christov, M. Cudic, P. Cudic Amino Acids 2017, 49(11):1867–1883.
DOI: 10.1007/s00726-017-2485-3
Antibodies elicited by the first non-viral prophylactic cancer vaccine show tumor-specificity and immunotherapeutic potential.
J.J. Lohmueller, S. Sato, L. Popova, I.M. Chu, M.A. Tucker, R. Barberena, G.M. Innocenti, M. Cudic, J.D. Ham, W.C. Cheung, R.D. Polakiewicz, O.J. Finn Sci. Rep. 2016, 6:31740.
DOI: 10.1038/srep31740
Thermodynamic Switch in Binding of Adhesion/Growth Regulatory Human Galectin-3 to Tumor-Associated TF Antigen (CD176) and MUC1 Glycopeptides.
M.C. Rodriguez, S. Yegorova, J.P. Pitteloud, A.E. Chavaroche, S. André, A. Ardá, D. Minond, J. Jiménez-Barbero, H.J. Gabius, M. Cudic Biochemistry 2015, 54(29):4462–4474.
DOI: 10.1021/acs.biochem.5b00555
Development of an AlphaScreen assay for discovery of inhibitors of low-affinity glycan-lectin interactions.
S. Yegorova, A.E. Chavaroche, M.C. Rodriguez, D. Minond, M. Cudic Anal. Biochem. 2013, 439(2):123–131.
DOI: 10.1016/j.ab.2013.04.028